Monotherapy data positive for BMS/AstraZeneca's novel antidiabetic
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb/AstraZeneca's antidiabetic drug dapagliflozin reduced blood glucose levels in the second of 10 Phase III trials, spurring further hopes for the first-in-class drug. It failed to induce weight loss, a secondary endpoint, however, tempering some expectations fostered by a recent report of the drug's first Phase III trial.